Intensifying systemic therapy improves outcomes in metastatic prostate cancer. As apalutamide and enzalutamide join abiraterone and docetaxel as treatment options for patients, the choice of therapy for individual patients becomes more complex. We anticipate precision targeted and immune therapies will build on the advances of recently completed large-scale trials.

中文翻译：

---

转移性前列腺癌的组合选择。

加强全身治疗可改善转移性前列腺癌的预后。随着阿帕鲁胺和恩杂鲁胺与阿比特龙和多西他赛一起作为患者的治疗选择，针对个别患者的治疗选择变得更加复杂。我们预计精确靶向和免疫疗法将基于最近完成的大规模试验的进展。